Tech Company Financing Transactions
Tolerance Bio Funding Round
Columbus Venture Partners, Ben Franklin Technology Partners and BioAdvance Ventures participated in a $17.2 million Seed venture round for Tolerance Bio. The financing round was announced on 10/15/2024.
Transaction Overview
Company Name
Announced On
10/15/2024
Transaction Type
Venture Equity
Amount
$17,200,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
808 Pinehurst Drive
Chapel Hill, NC 27517
USA
Chapel Hill, NC 27517
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergy. Abnormalities in immune tolerance underpin all these disease areas. The thymus is the essential organ for establishing and maintaining immune tolerance, yet it involutes over time, leading to increased susceptibility to immune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Francisco Leon
Chief Financial Officer
Justin Vogel
Chief Technical Officer
Yeh-Chuin Poh
Co-Founder
Holger Russ
Vice President
Paul Dunford
VP - Bus. Development
Phil Ball
Browse more venture capital transactions:
Prev: 10/15/2024: Path Robotics venture capital transaction
Next: 10/15/2024: Equilibrium Energy venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs